Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.4350
-0.0271 (-5.86%)
At close: Nov 5, 2026, 4:00 PM EST
0.4354
+0.0004 (0.09%)
After-hours: Nov 5, 2026, 7:37 PM EST
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or 26.09% compared to the previous year. That makes Outlook Therapeutics the 38,851st largest employer in the world and 5,664th in the United States.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
n/a
Profits / Employee
-$3,595,486
Market Cap
105.90M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Codexis | 146 |
| Coherus Oncology | 144 |
| Voyager Therapeutics | 141 |
| Nkarta | 106 |
| PolyPid | 75 |
| Armata Pharmaceuticals | 61 |
| TuHURA Biosciences | 22 |
OTLK News
- 27 days ago - Outlook Therapeutics announces Greg DiPasquale as chief commercial officer - TheFly
- 27 days ago - Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion - GlobeNewsWire
- 5 weeks ago - Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA - TheFly
- 5 weeks ago - Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 6 weeks ago - Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment - Business Wire
- 7 weeks ago - Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts